The long-term outcomes of patients with compensated hepatitis C virus-related cirrhosis and history of parenteral exposure in the United States.
about
Clinical Profiles of Chronic Hepatitis C in a Major County Medical Center Outpatient Setting in United States.Role of ledipasvir/sofosbuvir combination for genotype 1 hepatitis C virus infectionHepatitis C in human immunodeficiency virus co-infected individuals: Is this still a "special population"?Hepatitis C virus (HCV) infection in Africa: a reviewHepatitis C virus: A global viewThe natural history of hepatitis C virus (HCV) infection.Hepatitis C virus envelope glycoprotein co-evolutionary dynamics during chronic hepatitis CHelicase inhibitors as specifically targeted antiviral therapy for hepatitis CHepatitis C: a clinical reviewIdentification of a new marker of hepatocellular carcinoma by serum protein profiling of patients with chronic liver diseases.Clinical presentation of chronic hepatitis C in patients with end-stage renal disease and on hemodialysis versus those with normal renal function.Treatment of chronic hepatitis C in HIV-infected patients with compensated liver cirrhosis.Thrombocytopenia in Patients with Chronic Hepatitis C Virus InfectionRisk factors for liver-related mortality in chronic hepatitis C patients: a deceased case-living control study.Predicting clinical and histologic outcomes based on standard laboratory tests in advanced chronic hepatitis C.Nutrition and exercise in the management of liver cirrhosisViral, host and interferon-related factors modulating the effect of interferon therapy for hepatitis C virus infection.Sustained virologic response to antiviral therapy for chronic hepatitis C virus infection: a cure and so much more.Effects of immunosuppression and organ transplantation on the natural history and immunopathogenesis of hepatitis C virus infection.Is severe liver disease a common outcome for people with chronic hepatitis C?Relation of insulin resistance and liver fibrosis progression in patients with chronic hepatitis C virus infection.Interferon-based therapy decreases risks of hepatocellular carcinoma and complications of cirrhosis in chronic hepatitis C patients.A prospective study of the rate of progression in compensated, histologically advanced chronic hepatitis C.Viusid, a nutritional supplement, increases survival and reduces disease progression in HCV-related decompensated cirrhosis: a randomised and controlled trialPredictability of IL-28B-polymorphism on protease-inhibitor-based triple-therapy in chronic HCV-genotype-1 patients: A meta-analysisThe impact of antiviral therapy and the influence of metabolic cofactors on the outcome of chronic HCV infection.Pharmacotherapy of hepatocellular carcinoma.Effects of interferon treatment response on liver complications of chronic hepatitis C: 9-year follow-up study.Clinical significance of elevated alpha-fetoprotein (AFP) in patients with chronic hepatitis C, but not hepatocellular carcinoma.Reconstructing and predicting the hepatitis C virus epidemic in Greece: increasing trends of cirrhosis and hepatocellular carcinoma despite the decline in incidence of HCV infection.Hepatitis C: What is the nature of the problem?Patterns and predictors of treatment initiation and completion in patients with chronic hepatitis C virus infection.Alpha-fetoprotein and des-gamma-carboxy-prothrombin at twenty-four weeks after interferon-based therapy predict hepatocellular carcinoma development.Incidence of hepatocellular carcinoma among US patients with cirrhosis of viral or nonviral etiologiesTreatment of hepatitis C in compensated cirrhotic patients is equally effective before and after liver transplantationSASLT practice guidelines: management of hepatitis C virus infection.Long-term effects of interferon-based therapy for chronic hepatitis C.Association of IL28B genotype with fibrosis progression and clinical outcomes in patients with chronic hepatitis C: a longitudinal analysis.Comparison of liver biopsy and transient elastography based on clinical relevance.Seronegative hepatitis C virus infection.
P2860
Q24791398-C7C5485D-1502-44B1-A473-004DCB0476FAQ26740216-4A1A7F18-0C06-40EF-BE8E-2B05C2C914F7Q26798469-FFF66B15-3D9E-42C6-A8D5-CE263BA56693Q26824322-A4811EEA-E279-4701-9FF1-65E0595B3B5EQ26862531-8D74D6F6-55FF-4D8E-93B4-777660DB47E9Q27473116-3AA09A99-E34C-4A05-8043-38CA63AA2588Q27486537-BD777D36-3E50-4662-AA05-07740CFFDF22Q27488958-6157C59C-6B15-469D-952E-DC7F326447C3Q27490788-6C1F8AA4-0A12-4BE5-BAD8-904ACD4880F0Q33211462-421F492C-FEEC-45FC-AB67-3E0BDB70EB29Q33368159-EB34D008-35A0-4935-A15B-B56E8C1883ECQ33391761-69CF684C-D651-4D0D-A75D-5D9A9A6B4366Q33440130-CCD5BD90-D3BE-4E8E-86BC-F3B5489FDEAFQ33594968-A8C929BE-A164-43A0-95FD-A65E1FC93CC0Q33618516-5EC710CB-8DBB-4532-B6D7-49154C028153Q33780141-AD42F9A8-0ABD-4A32-A40E-DD96AEFAA548Q34129547-109CD11B-9C10-4D78-831C-14E4675CEFE2Q34172595-61D91A03-65C3-4745-9F92-4286680FC742Q34294938-35D15E4B-986D-448E-ACEC-CA58E03DB2E3Q34619377-8B4FFD3F-A0B3-48F9-9409-7923F57138A8Q34747549-3DE9C4F1-30EE-4DCF-A5E6-9D45A8701D89Q34876460-A0264A9B-6A09-4403-91A2-5EF3B1C292EEQ35131882-2FD1DF3B-8B66-4ABF-A02D-A8DAB9F12685Q35322521-A9878ECF-C7F4-4E94-8DE5-4D4CBE3C46CFQ35370579-4E0B5211-75DC-4C13-82F0-AD74854F64AAQ35590977-F242FC48-FFED-431C-8F56-AB5B872FBA4FQ35593957-C61EAF11-EED9-4E58-9745-C7552EE72E95Q35747990-CDBD7764-3805-42F9-8530-65FD2740BA25Q35765109-DCC1CF89-F33D-4EC5-965B-6D82B0AA07FFQ35824825-17B79C58-C81D-49B8-97A0-5A3D08CBDF1DQ35882845-68D82F25-90C3-4FDF-BA49-C6237A85B4C4Q35905912-4B83F377-5B31-43E6-BAB2-175132BF6F9CQ36329125-355F05DC-E2AD-4C08-A97A-163197E916B5Q36438943-B5517A2F-903F-4923-804B-3ED802527673Q36897917-FD75D1FC-A592-4A96-8B4E-08847760DAB9Q37019765-B9CCF3BC-8B6A-4218-93D1-85EC9B34A224Q37034868-08C33F3A-5BAC-48F0-BC42-56FF05E95CC8Q37135105-90667D7C-26A7-455E-9409-358E3CA509C0Q37141294-67A2E949-B0E1-474A-9708-6BFCE08D5EC8Q37631608-564E8CCD-DD8F-494E-8F09-B7C1104E640E
P2860
The long-term outcomes of patients with compensated hepatitis C virus-related cirrhosis and history of parenteral exposure in the United States.
description
1999 nî lūn-bûn
@nan
1999年の論文
@ja
1999年学术文章
@wuu
1999年学术文章
@zh
1999年学术文章
@zh-cn
1999年学术文章
@zh-hans
1999年学术文章
@zh-my
1999年学术文章
@zh-sg
1999年學術文章
@yue
1999年學術文章
@zh-hant
name
The long-term outcomes of pati ...... exposure in the United States.
@en
The long-term outcomes of pati ...... exposure in the United States.
@nl
type
label
The long-term outcomes of pati ...... exposure in the United States.
@en
The long-term outcomes of pati ...... exposure in the United States.
@nl
prefLabel
The long-term outcomes of pati ...... exposure in the United States.
@en
The long-term outcomes of pati ...... exposure in the United States.
@nl
P356
P1433
P1476
The long-term outcomes of pati ...... exposure in the United States.
@en
P304
P356
10.1002/HEP.510290424
P407
P577
1999-04-01T00:00:00Z